Goldman Sachs Group Inc. Sells 16,413 Shares of Anteris Technologies Global Corp. $AVR

Goldman Sachs Group Inc. lessened its holdings in Anteris Technologies Global Corp. (NASDAQ:AVR) by 36.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 28,126 shares of the company’s stock after selling 16,413 shares during the period. Goldman Sachs Group Inc. owned about 0.08% of Anteris Technologies Global worth $102,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Corebridge Financial Inc. purchased a new position in shares of Anteris Technologies Global in the first quarter worth $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Anteris Technologies Global during the first quarter valued at $32,000. Deutsche Bank AG purchased a new position in Anteris Technologies Global during the first quarter valued at $59,000. Nuveen LLC purchased a new position in Anteris Technologies Global during the first quarter valued at $71,000. Finally, Persistent Asset Partners Ltd purchased a new position in Anteris Technologies Global during the first quarter valued at $85,000.

Anteris Technologies Global Price Performance

NASDAQ:AVR opened at $4.36 on Tuesday. The company’s 50-day moving average price is $4.08 and its 200-day moving average price is $4.05. Anteris Technologies Global Corp. has a twelve month low of $2.34 and a twelve month high of $8.79.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Monday, August 11th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). The business had revenue of $0.62 million for the quarter, compared to the consensus estimate of $0.58 million. On average, research analysts expect that Anteris Technologies Global Corp. will post -2.66 earnings per share for the current year.

Anteris Technologies Global Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.